Ocular FIP treatment moves further into routine practice

CURRENT BRIEF VERSION: A new VETgirl podcast is spotlighting a practical shift in how veterinarians think about ocular feline infectious peritonitis, or FIP: antiviral treatment is no longer theoretical background noise, but part of real-world case management. The broader context is what has changed most. GS-441524 and remdesivir now have a much larger evidence base behind them, including published reviews, retrospective studies, and guideline updates that support dose adjustments for cats with ocular or neurologic involvement. In the U.S., access also changed materially in 2024, when the FDA said it did not intend to enforce approval requirements for compounded GS-441524 prescribed by veterinarians for specific feline patients under Guidance for Industry #256, and compounded oral GS-441524 became available through pharmacy channels soon after. The podcast also helps ground that shift in day-to-day recognition: ocular FIP may present with vision changes and ocular inflammation, sometimes as the main presenting feature, with anterior findings such as keratic precipitates, iris color change, dyscoria, hyphema, hypopyon, or fibrinous exudate, and posterior changes including retinal hemorrhage, vascular tortuosity, retinal detachment, or gray-white fundic lesions. (fda.gov)

Why it matters: For veterinary professionals, ocular FIP is increasingly a treatment-planning problem, not just a diagnostic dead end. Recent guidance and reviews indicate that cats with ocular signs often need higher antiviral exposure than uncomplicated effusive cases, because ocular and neurologic disease can require more aggressive dosing and, in some protocols, divided dosing. The newer VETgirl coverage also reinforces two practical points from real-world FIP management: response can look dramatic within the first week, but early clinical improvement does not necessarily mean viral clearance, and treatment decisions still need to be tied to follow-up exams and objective trends where possible. Evidence remains imperfect, but the direction is consistent: earlier recognition, confirmation where feasible, and prompt antiviral therapy can improve outcomes, while undertreatment raises the risk of persistent inflammation, relapse, or progression. (pubmed.ncbi.nlm.nih.gov)

What to watch: Expect more protocol refinement around dose intensity, treatment duration, and monitoring for ocular and neuro-ocular FIP as newer case series, reviews, and practice guidelines continue to accumulate. That includes growing interest in whether higher-dose induction strategies, acute phase proteins such as serum amyloid A and alpha-1 acid glycoprotein, and albumin:globulin trends can help guide when treatment can safely stop rather than relying on appearance alone. (pubmed.ncbi.nlm.nih.gov)